Carcinomas - Pipeline Review, H2 2012

Description: Carcinomas – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Carcinomas - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinomas. Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Carcinomas.
- A review of the Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Carcinomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Carcinomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2 List of Tables 11
List of Figures 15
Introduction 16
REPORT COVERAGE 16
Carcinomas Overview 17
Therapeutics Development 18
An Overview of Pipeline Products for Carcinomas 18
Carcinomas Therapeutics under Development by Companies 20
Carcinomas Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 39
Comparative Analysis 39
Mid Clinical Stage Products 40
Mechanism of Action 232
R&D Progress 232
cyclophosphamide - Drug Profile 233
Product Description 233
Mechanism of Action 233
R&D Progress 233
Fluorouracil + Leucovorin + Oxaliplatin + Irinotecan - Drug Profile 234
Product Description 234
Mechanism of Action 234
R&D Progress 235
Flutamide + Goserelin + Leuprolide - Drug Profile 236
Product Description 236
Mechanism of Action 236
R&D Progress 237
sorafenib tosylate - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Calcium + Oxaliplatin - Drug Profile 239
Product Description 239
Mechanism of Action 239
R&D Progress 240
C225 + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 243
Product Description 243
Mechanism of Action 243
R&D Progress 243
cisplatin - Drug Profile 244
Product Description 244
Mechanism of Action 244
R&D Progress 244
IMC-1121B + FOLFIRI - Drug Profile 246
Product Description 246
Mechanism of Action 246
R&D Progress 246
Erbitux + Radiation Therapy - Drug Profile 248
Product Description 248
Mechanism of Action 248
R&D Progress 248
Paclitaxel + RAD001 - Drug Profile 249
Product Description 249
Mechanism of Action 249
R&D Progress 249
IMC-1121B + Paclitaxel - Drug Profile 250
Product Description 250
Mechanism of Action 250
R&D Progress 250
Trastuzumab + Carboplatin + Paclitaxel - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 252
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
Gemcitabine + Human Epidermal Growth Factor Receptor Type I - Drug Profile 255
Product Description 255
Mechanism of Action 255
R&D Progress 255
TPF Induction Chemotherapy + Radiotherapy - Drug Profile 256
Boehringer Ingelheim GmbH, H2 2012 77
F. Hoffmann-La Roche Ltd., H2 2012 78
Abbott Laboratories, H2 2012 79
Sequella, Inc., H2 2012 80
Shionogi & Co., Ltd., H2 2012 81
Amgen Inc., H2 2012 82
Sanofi-Aventis, H2 2012 83
AstraZeneca PLC, H2 2012 84
Eli Lilly and Company, H2 2012 85
GlaxoSmithKline plc, H2 2012 86
Genentech, Inc., H2 2012 87
Gilead Sciences, Inc., H2 2012 88
Merck & Co., Inc., H2 2012 89
YM BioSciences Inc., H2 2012 90
Delcath Systems, Inc., H2 2012 91
Celltrion, Inc., H2 2012 92
Millennium Pharmaceuticals, Inc., H2 2012 93
Novartis AG, H2 2012 94
Astellas Pharma Inc., H2 2012 95
Eisai Co., Ltd., H2 2012 96
Pfizer Inc., H2 2012 97
Taiho Pharmaceutical Co., Ltd., H2 2012 98
Takara Holdings Inc., H2 2012 99
Yakult Honsha Co., Ltd., H2 2012 100
Aduro BioTech, H2 2012 101
CEL-SCI Corporation, H2 2012 102
Celgene Corporation, H2 2012 103
Merck KGaA, H2 2012 104
Alchemia Limited, H2 2012 105
Celldex Therapeutics, Inc., H2 2012 106
Momenta Pharmaceuticals, Inc., H2 2012 107
Idera Pharmaceuticals, Inc., H2 2012 108
Lorus Therapeutics Inc, H2 2012 109
AVAX Technologies, Inc., H2 2012 110
NexMed, Inc., H2 2012 111
Clinuvel Pharmaceuticals Limited, H2 2012 112
Oncothyreon Inc, H2 2012 113
Peregrine Pharmaceuticals, Inc., H2 2012 114
TopoTarget A/S, H2 2012 115
Institute of Cancer Research, H2 2012 116
Threshold Pharmaceuticals, Inc., H2 2012 117
Provectus Pharmaceuticals, Inc., H2 2012 118
Proteo, Inc., H2 2012 119
Oryzon, H2 2012 120
PCI Biotech Holding ASA, H2 2012 121
Spectrum Pharmaceuticals, Inc., H2 2012 122
GANYMED Pharmaceuticals AG, H2 2012 123
Nerviano Medical Sciences S.r.l., H2 2012 124
Glycotope GmbH, H2 2012 125
immatics biotechnologies GmbH, H2 2012 126
Merrimack Pharmaceuticals, Inc., H2 2012 127
Jennerex Biotherapeutics, Inc., H2 2012 128
BioCancell Therapeutics, Inc., H2 2012 129
Omeros Corporation, H2 2012 130
Cellceutix Corporation, H2 2012 131
Kinex Pharmaceuticals, LLC, H2 2012 132
Cannabis Science, Inc., H2 2012 133
Genelux Corporation, H2 2012 134
Nereus Pharmaceuticals, Inc., H2 2012 135
Viventia Biotechnologies Inc., H2 2012 136
Lytx Biopharma AS, H2 2012 137
IRX Therapeutics, Inc., H2 2012 138
Eleison Pharmaceuticals, Inc., H2 2012 139
Vakzine Projekt Management GmbH, H2 2012 140
Eurofarma, H2 2012 141
Laboratorio Elea S.A.C.I.F. and A, H2 2012 142
Biotech Pharmaceuticals Co., Ltd., H2 2012 143
Assessment by Monotherapy Products, H2 2012 144
Assessment by Combination Products, H2 2012 145
Carcinomas Therapeutics – Drug Profile Updates 259
Carcinomas Therapeutics – Discontinued Products 267
Carcinomas Therapeutics – Discontinued Products (Contd..1) 268
Carcinomas Therapeutics – Discontinued Products (Contd..2) 269
Carcinomas Therapeutics – Discontinued Products (Contd..3) 270
Carcinomas Therapeutics – Discontinued Products (Contd..4) 271
Carcinomas Therapeutics – Discontinued Products (Contd..5) 272
Carcinomas Therapeutics – Discontinued Products (Contd..6) 273
Carcinomas Therapeutics – Dormant Products 274
Carcinomas Therapeutics – Dormant Products (Contd..1) 275
Carcinomas Therapeutics – Dormant Products (Contd..2) 276
Carcinomas Therapeutics – Dormant Products (Contd..3) 277
Carcinomas Therapeutics – Dormant Products (Contd..4) 278
Carcinomas Therapeutics – Dormant Products (Contd..5) 279
Carcinomas Therapeutics – Dormant Products (Contd..6) 280
Carcinomas Therapeutics – Dormant Products (Contd..7) 281
Carcinomas Therapeutics – Dormant Products (Contd..8) 282
Carcinomas Therapeutics – Dormant Products (Contd..9) 283
Carcinomas Therapeutics – Dormant Products (Contd..10) 284
Carcinomas Therapeutics – Dormant Products (Contd..11) 285
Carcinomas Therapeutics – Dormant Products (Contd..12) 286
Carcinomas Therapeutics – Dormant Products (Contd..13) 287
Carcinomas Therapeutics – Dormant Products (Contd..14) 288
Carcinomas Therapeutics – Dormant Products (Contd..15) 289
Carcinomas Therapeutics – Dormant Products (Contd..16) 290
Carcinomas Therapeutics – Dormant Products (Contd..17) 291
Carcinomas Therapeutics – Dormant Products (Contd..18) 292
Carcinomas Therapeutics – Dormant Products (Contd..19) 293
Carcinomas Therapeutics – Dormant Products (Contd..20) 294
Carcinomas Therapeutics – Dormant Products (Contd..21) 295
Carcinomas Therapeutics – Dormant Products (Contd..22) 296
Carcinomas Therapeutics – Dormant Products (Contd..23) 297
Carcinomas Therapeutics – Dormant Products (Contd..24) 298
Carcinomas Therapeutics – Dormant Products (Contd..25) 299
Carcinomas Therapeutics – Dormant Products (Contd..26) 300
Carcinomas Therapeutics – Dormant Products (Contd..27) 301
Carcinomas Therapeutics – Dormant Products (Contd..28) 302
Carcinomas Therapeutics – Dormant Products (Contd..29) 303
Carcinomas Therapeutics – Dormant Products (Contd..30) 304
Carcinomas Therapeutics – Dormant Products (Contd..31) 305
Carcinomas Therapeutics – Dormant Products (Contd..32) 306
Carcinomas Therapeutics – Dormant Products (Contd..33) 307
Carcinomas Therapeutics – Dormant Products (Contd..34) 308
Carcinomas Therapeutics – Dormant Products (Contd..35) 309

List of Figures
Number of Products under Development for Carcinomas, H2 2012 18
Products under Development for Carcinomas – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 39
Mid Clinical Stage Products, H2 2012 40
Early Clinical Stage Products, H2 2012 41
Discovery and Pre-Clinical Stage Products, H2 2012 42
Assessment by Monotherapy Products, H2 2012 144
Assessment by Combination Products, H2 2012 145

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2366355/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Carcinomas - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2366355/
Office Code: SCD23GF3

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World